Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca, BMY To Target Disease Management And Primary Care Synergies With Amylin Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

In acquiring Amylin at a hefty premium, Bristol-Myers Squibb and its partner AstraZeneca are highly optimistic about prospects for Amylin’s GLP-1 franchise, and also hope to leverage their existing infrastructure as their fledgling diabetes franchise struggles to meet expectations.

You may also be interested in...

Focusing R&D In The Age Of Speed: An Interview With Bristol-Myers Squibb CSO Francis Cuss

Since being promoted to chief scientific officer of Bristol-Myers Squibb, effective July 2013, company veteran Francis Cuss says he has aimed for continuity while staying flexible to respond to breaking science. In an interview at the J.P. Morgan Healthcare Conference in January, he explains the company’s thinking when it comes to focusing on particular disease areas with the highest unmet need and potential for speedy development.

Patent Cliff Continues in 2014, But Not So Steeply

Most of big pharma has crossed to the other side of the patent cliff and put their biggest losses behind them in 2012 and 2013, but a few major blockbusters will face new generic competition this year, including Nexium, Copaxone, and Nasonex.

What To Do With $3.4 Billion? Deals And Dividends Says BMS’ Andreotti

BMS plans to use the $3.4 billion it will receive shortly from AstraZeneca for selling its stake in their diabetes JV to fund a dividend increase, business development and possibly a share repurchasing program, Andreotti tells investors at the Goldman Sachs meeting.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts